Omega Flex, Inc. — Q1 2020 Form 10-Q Summary
Business Context and Reporting Period
Omega Flex manufactures and sells flexible metal hose, proprietary fittings, and related accessories for residential and commercial construction, healthcare, pharmaceutical, petrochemical, transportation, and other industrial applications. The company operates as one reportable segment, with manufacturing facilities in the United States and the United Kingdom. This filing covers the three months ended March 31, 2020; financial statements are unaudited and amounts are in thousands except per-share data.
Financial Performance and Position
| Metric | Q1 2020 | Q1 2019 | Change |
|---|---|---|---|
| Net sales | $25,266 | $26,788 | Down 5.7% |
| Gross profit | $15,769 | $16,946 | Down 6.9% |
| Gross margin | 62.4% | 63.3% | Down 0.9 percentage points |
| Operating profit | $5,845 | $5,591 | Up 4.5% |
| Operating margin | 23.1% | 20.9% | Up 2.2 percentage points |
| Net income attributable to Omega Flex | $4,344 | $4,382 | Down 0.9% |
| Basic and diluted EPS | $0.43 | $0.43 | No change |
| Cash flow from operations | $751 | $(956) | Improved by $1,707 |
Cash and cash equivalents were $13,834 at March 31, 2020, compared with $16,098 at December 31, 2019. Total assets were $56,518 and total shareholders’ equity was $38,940. Accounts receivable were $15,524, inventories were $11,222, and the allowance for credit losses was $1,103.
The company had no borrowings under its unsecured $15,000 revolving credit facility at March 31, 2020 and was in compliance with its debt covenants. Subsequent to quarter-end, it borrowed the full $15,000 capacity at a stated prime rate of 3.50% to preserve liquidity during the COVID-19 crisis. Management stated that existing cash and borrowing capacity were sufficient for anticipated needs for at least the next twelve months.
Investing cash outflow was $145, primarily for capital expenditures, compared with $8,115 in Q1 2019. Financing cash outflow was $2,826 for dividends. A $0.28 per-share dividend declared March 31, 2020 was paid April 17, 2020.
Material Changes Versus the Prior Comparable Period
- Sales declined primarily because of lower unit volume, partly offset by pricing actions intended to mitigate material-cost pressure and protect margins.
- Gross margin declined modestly, while operating margin increased because general and administrative expense fell 22.7% and engineering expense fell 16.5%.
- General and administrative expense benefited from a $1,213 change in phantom-stock compensation, from $746 of expense in Q1 2019 to $467 of compensation income in Q1 2020, and from lower legal and product-liability defense costs.
- Interest income decreased to $45 from $220 because of lower cash balances and reduced short-term investment activity after the large December 2019 special dividend.
- Operating cash flow improved because of collections of accounts receivable and working-capital timing, partially offset by payments of prior-year compensation, commissions, and incentives.
- The company adopted updated goodwill impairment and expected-credit-loss standards in 2020; management reported no material financial-statement impact.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no quantitative full-year revenue or earnings guidance. Management stated that Q1 results are not necessarily indicative of full-year performance because the COVID-19 pandemic was accelerating after quarter-end.
COVID-19 had not materially adversely affected Q1 results, but management expected reduced residential and commercial construction activity, particularly in Europe, potentially continuing into Q2 and beyond. Demand for MediTrac medical-gas piping and certain pharmaceutical applications was increasing but had not fully offset weaker residential-construction sales. U.S. production continued with safety measures; the U.K. facility operated with reduced staff and furloughs. The company reported no significant supplier disruptions.
- Management identified substantial uncertainty regarding the duration and severity of COVID-19, construction activity, medical-product demand, government restrictions, supply conditions, and future liquidity needs.
- A prolonged pandemic could trigger an interim goodwill impairment test; no triggering event was identified through March 31, 2020.
- The company received a $2,453 SBA Paycheck Protection Program loan on April 7, 2020 and intended to repay it by May 7, 2020 in light of subsequent Treasury guidance.
- Pending product-liability matters, including a Missouri putative class action involving alleged lightning damage, remain unresolved. Recorded litigation-related liabilities were $175. The estimated aggregate maximum exposure for current open claims, excluding the Missouri class action, was approximately $3,500, subject to insurance deductibles and retentions.
- A U.K. legal dispute presented a potential loss estimated at $200 to $500; no liability was recorded because the loss was not considered probable and the company could potentially recover amounts if successful.
- One customer represented more than 10% of accounts receivable and more than 10% of sales in both Q1 2020 and Q1 2019, creating customer-concentration risk.
Most Important Facts for Investors to Verify
- Confirm the timing, terms, and repayment or forgiveness status of the $15,000 post-quarter-end revolver borrowing and the $2,453 PPP loan.
- Monitor COVID-19 effects on residential construction, European operations, medical-gas demand, and the company’s ability to sustain margins.
- Review developments, insurance coverage, reserves, and potential exposure related to the Missouri class action and other product-liability claims.
- Assess the effect of the major December 2019 special dividend and ongoing quarterly dividends on cash balances and liquidity.
- Track customer concentration, foreign-currency movements, credit-loss estimates, and potential goodwill impairment.